Veracyte, Inc. and Supernus Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

Biotech Giants: A Decade of Profit Growth

__timestampSupernus Pharmaceuticals, Inc.Veracyte, Inc.
Wednesday, January 1, 201411628700021584000
Thursday, January 1, 201513600400028006000
Friday, January 1, 201620301700039623000
Sunday, January 1, 201728702300043758000
Monday, January 1, 201839354100058930000
Tuesday, January 1, 201937609500083845000
Wednesday, January 1, 202046793800076028000
Friday, January 1, 2021504714000145114000
Saturday, January 1, 2022580017000194954000
Sunday, January 1, 2023523742000248148000
Loading chart...

Igniting the spark of knowledge

A Decade of Growth: Veracyte, Inc. vs. Supernus Pharmaceuticals, Inc.

In the ever-evolving landscape of biotechnology and pharmaceuticals, Veracyte, Inc. and Supernus Pharmaceuticals, Inc. have demonstrated remarkable growth over the past decade. From 2014 to 2023, Supernus Pharmaceuticals has consistently outperformed Veracyte in terms of gross profit, showcasing a robust upward trajectory. Starting at approximately $116 million in 2014, Supernus saw its gross profit soar by over 350% to reach around $524 million by 2023. Meanwhile, Veracyte, Inc. began with a modest $22 million in 2014, but experienced a significant increase of over 1,000%, reaching nearly $248 million in 2023. This impressive growth highlights the dynamic nature of the industry and the potential for companies to expand rapidly. As we look to the future, these trends underscore the importance of innovation and strategic planning in maintaining competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025